Bull & Lifshitz, LLP Announces Investigation of the Acquisition of Facet Biotech Corporation by Abbott Laboratories

Bull & Lifshitz, LLP announces an investigation into possible breaches of fiduciary duty in connection with the proposed sale of Facet Biotech Corporation (NASDAQ: FACT) (referred to as "Facet Biotech”) to Abbott Laboratories (“Abbott”).

Under the terms of the agreement, Abbott will commence a tender offer to purchase all outstanding shares of Facet Biotech shares for $27 per share in cash.

Bull & Lifshitz, LLP's investigation is focused on whether the proposed deal provides adequate value to the Company’s shareholders.

If you are a holder of Facet Biotech stock and want to discuss your legal rights, you may e-mail or call Bull & Lifshitz, LLP who will, without obligation or cost to you, attempt to answer your questions.

If you are a shareholder of Facet Biotech and would like more information about our investigation, please contact Peter D. Bull, Esq. by telephone at: [phone] or by sending an e-mail including your contact information to: [e-mail]. All e-mail correspondence should make reference to Facet Biotech.

Bull & Lifshitz, LLP is a New York City-based law firm with significant experience representing investors in merger-related shareholder class actions, shareholder derivative actions, and securities fraud class actions. For more information about the firm, please visit our website at www.nyclasslaw.com.

ATTORNEY ADVERTISING. © 2010 Bull & Lifshitz, LLP. The law firm responsible for this advertisement is Bull & Lifshitz, LLP, 18 East 41st Street, New York, New York 10017, [phone]. Prior results do not guarantee or predict a similar outcome with respect to any future matter.